Stock Track | Argenx SE Soars 5.07% Intraday on FDA Approval for Vyvgart Label Expansion
Stock Track
May 11
Argenx SE (ARGX) saw its stock price soar 5.07% during intraday trading on Monday, following a significant regulatory milestone announced over the weekend.
The surge comes after the company announced it secured U.S. Food and Drug Administration approval for a label expansion of its drugs Vyvgart and Vyvgart Hytrulo. The approval extends the use of the treatments to all serotypes of adult patients living with generalized myasthenia gravis.
The regulatory decision was supported by positive data from a phase 3 trial, which demonstrated rapid, significant, and sustained improvements in symptoms across serotypes. This expansion is expected to broaden the addressable patient population for the company's flagship products.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.